Blog

Home  /  News   /  The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available

The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available

WP5-SA4 – Updated report including the complete dataset on indirect comparisons published on EUnetHTA homepage.

Find the Joint Assessment here.